Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : OTC)

• Company Description    Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $8.80 Daily Weekly Monthly 20 Day Moving Average: 3,760 shares Shares Outstanding: 0.56 (millions) Market Capitalization: $4.94 (millions) Beta: 2.43 52 Week High: $45.60 52 Week Low: $4.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.57% -1.24% 12 Week 62.78% 47.79% Year To Date -72.13% -75.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BOULEVARD SUITE 740 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-655-4168 fax: - investors@sprucebio.com http://www.sprucebiosciences.com

• General Corporate Information    Officers Javier Szwarcberg - Chief Executive Officer Michael Grey - Executive Chairman Samir Gharib - President and Chief Financial Officer Tiba Aynechi - Director Percival Barretto-Ko - Director Peer Information Spruce Biosciences, Inc. (CORR.) Spruce Biosciences, Inc. (RSPI) Spruce Biosciences, Inc. (CGXP) Spruce Biosciences, Inc. (BGEN) Spruce Biosciences, Inc. (GTBP) Spruce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 85209E208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/10/25 Share - Related Items Shares Outstanding: 0.56 Most Recent Split Date: 8.00 (0.01:1) Beta: 2.43 Market Capitalization: $4.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-15.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/10/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.38 Price/Cash Flow: - Price / Sales: 1.01 EPS Growth vs. Year Ago Period: 78.84% vs. Previous Quarter: 85.45% Sales Growth vs. Year Ago Period: -75.86% vs. Previous Quarter: 15.78% ROE 06/30/25 - -177.45 03/31/25 - -143.15 12/31/24 - -102.86 ROA 06/30/25 - -118.06 03/31/25 - -101.99 12/31/24 - -77.60 Current Ratio 06/30/25 - 2.60 03/31/25 - 1.95 12/31/24 - 2.90 Quick Ratio 06/30/25 - 2.60 03/31/25 - 1.95 12/31/24 - 2.90 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,079.94 Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,079.94 Pre-Tax Margin 06/30/25 - -3,721.17 03/31/25 - -1,906.22 12/31/24 - -1,079.94 Book Value 06/30/25 - 23.47 03/31/25 - 27.28 12/31/24 - 52.47 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.43

Powered by Zacks Investment Research ©